4506
Sumitomo Pharma Co., Ltd.
2026/03/02
Sumitomo Pharma has formulated the growth strategy 'Boost 2028' covering fiscal years 2026 to 2028, aiming for over 350 billion yen in sales from Orgovix and Gemtesa, ROE above 10%, and equity ratio over 50% by fiscal 2028.
